SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Canopy Growth Corp
Date: Jan. 13, 2026 · CIK: 0001737927 · Accession: 0000000000-26-000382

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-292635

Date
January 13, 2026
Author
Division of
Form
UPLOAD
Company
Canopy Growth Corp

Letter

Re: Canopy Growth Corp Registration Statement on Form S-3 Filed January 9, 2026 File No. 333-292635 Dear Christelle Gedeon:

January 13, 2026

Christelle Gedeon Chief Business Development & Corporate Affairs Officer Canopy Growth Corp 1015 15th Street N.W., Suite 1000 Washington, DC 20005

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jimmy McNamara at 202-551-7349 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Yariv Katz

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 January 13, 2026

Christelle Gedeon
Chief Business Development & Corporate Affairs Officer
Canopy Growth Corp
1015 15th Street N.W., Suite 1000
Washington, DC 20005

 Re: Canopy Growth Corp
 Registration Statement on Form S-3
 Filed January 9, 2026
 File No. 333-292635
Dear Christelle Gedeon:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jimmy McNamara at 202-551-7349 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Yariv Katz
</TEXT>
</DOCUMENT>